

Shevanthi Nayagam

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6238317/publications.pdf>

Version: 2024-02-01

46
papers

3,365
citations

331670

21
h-index

233421

45
g-index

51
all docs

51
docs citations

51
times ranked

5843
citing authors

#	ARTICLE	IF	CITATIONS
1	The impact of COVID-19 and strategies for mitigation and suppression in low- and middle-income countries. <i>Science</i> , 2020, 369, 413-422.	12.6	718
2	Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 135-184.	8.1	370
3	Requirements for global elimination of hepatitis B: a modelling study. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 1399-1408.	9.1	279
4	The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa. <i>Gut</i> , 2016, 65, 1369-1376.	12.1	267
5	Endoscopic ultrasound guided fine needle aspiration for the diagnosis of pancreatic cystic neoplasms: A meta-analysis. <i>Pancreatology</i> , 2013, 13, 48-57.	1.1	238
6	Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. <i>Lancet</i> , The, 2019, 393, 1319-1329.	13.7	212
7	Adapting hospital capacity to meet changing demands during the COVID-19 pandemic. <i>BMC Medicine</i> , 2020, 18, 329.	5.5	144
8	Estimating the health impact of vaccination against ten pathogens in 98 low-income and middle-income countries from 2000 to 2030: a modelling study. <i>Lancet</i> , The, 2021, 397, 398-408.	13.7	144
9	Acceptability and feasibility of a screen-and-treat programme for hepatitis B virus infection in The Gambia: the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) study. <i>The Lancet Global Health</i> , 2016, 4, e559-e567.	6.3	137
10	Viral hepatitis in resource-limited countries and access to antiviral therapies: current and future challenges. <i>Future Virology</i> , 2013, 8, 371-380.	1.8	110
11	Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in The Gambia: an economic modelling analysis. <i>The Lancet Global Health</i> , 2016, 4, e568-e578.	6.3	91
12	Clinical Characteristics and Predictors of Outcomes of Hospitalized Patients With Coronavirus Disease 2019 in a Multiethnic London National Health Service Trust: A Retrospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e4047-e4057.	5.8	81
13	Food intake increases liver stiffness measurements and hampers reliable values in patients with chronic hepatitis B and healthy controls: the PROLIFICA experience in The Gambia. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 188-196.	3.7	56
14	Development of a simple score based on HBeAg and ALT for selecting patients for HBV treatment in Africa. <i>Journal of Hepatology</i> , 2018, 69, 776-784.	3.7	55
15	In-hospital mortality is associated with inflammatory response in NAFLD patients admitted for COVID-19. <i>PLoS ONE</i> , 2020, 15, e0240400.	2.5	54
16	Lives saved with vaccination for 10 pathogens across 112 countries in a pre-COVID-19 world. <i>ELife</i> , 2021, 10, .	6.0	50
17	The impact of the timely birth dose vaccine on the global elimination of hepatitis B. <i>Nature Communications</i> , 2021, 12, 6223.	12.8	48
18	The investment case for hepatitis B and C in South Africa: adaptation and innovation in policy analysis for disease program scale-up. <i>Health Policy and Planning</i> , 2018, 33, 528-538.	2.7	34

#	ARTICLE	IF	CITATIONS
19	The global burden of chronic hepatitis B virus infection: comparison of country-level prevalence estimates from four research groups. <i>International Journal of Epidemiology</i> , 2021, 50, 560-569.	1.9	29
20	Hepatitis B Core-related Antigen: An Alternative to Hepatitis B Virus DNA to Assess Treatment Eligibility in Africa. <i>Clinical Infectious Diseases</i> , 2020, 70, 1442-1452.	5.8	25
21	Investment Case for a Comprehensive Package of Interventions Against Hepatitis B in China: Applied Modeling to Help National Strategy Planning. <i>Clinical Infectious Diseases</i> , 2021, 72, 743-752.	5.8	25
22	Mother-to-child transmission of hepatitis B: What more needs to be done to eliminate it around the world?. <i>Journal of Viral Hepatitis</i> , 2020, 27, 342-349.	2.0	24
23	Aiming at the Global Elimination of Viral Hepatitis: Challenges Along the Care Continuum. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofx252.	0.9	22
24	Economic evaluations of HBV testing and treatment strategies and applicability to low and middle-income countries. <i>BMC Infectious Diseases</i> , 2017, 17, 692.	2.9	16
25	The impact of the COVID-19 pandemic on patterns of attendance at emergency departments in two large London hospitals: an observational study. <i>BMC Health Services Research</i> , 2021, 21, 1008.	2.2	15
26	How can the public health impact of vaccination be estimated?. <i>BMC Public Health</i> , 2021, 21, 2049.	2.9	11
27	Understanding the Potential Impact of Different Drug Properties on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Transmission and Disease Burden: A Modelling Analysis. <i>Clinical Infectious Diseases</i> , 2022, 75, e224-e233.	5.8	10
28	Progress towards elimination of mother-to-child transmission of hepatitis B virus infection in China: a modelling analysis. <i>Bulletin of the World Health Organization</i> , 2021, 99, 10-18.	3.3	10
29	Strategies for Global Elimination of Chronic HBV Infection: 2019 Update. <i>Current Hepatology Reports</i> , 2019, 18, 300-309.	0.9	9
30	Screening strategies to prevent mother-to-child transmission of hepatitis B in sub-Saharan Africa. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 222-223.	8.1	8
31	Modelling hepatitis B virus infection and impact of timely birth dose vaccine: A comparison of two simulation models. <i>PLoS ONE</i> , 2020, 15, e0237525.	2.5	8
32	Characteristics and outcomes of clinically diagnosed RT-PCR swab negative COVID-19: a retrospective cohort study. <i>Scientific Reports</i> , 2021, 11, 2455.	3.3	8
33	Cost-effectiveness of strategies to improve HCV screening, linkage to care and treatment in remand prison settings in England. <i>Liver International</i> , 2020, 40, 2950-2960.	3.9	7
34	Cost effectiveness of simplified HCV screening-and-treatment interventions for people who inject drugs in Dar-es-Salaam, Tanzania. <i>International Journal of Drug Policy</i> , 2022, 99, 103458.	3.3	6
35	Strengthening vaccine confidence during the COVID-19 pandemic: A new opportunity for global hepatitis B virus elimination. <i>Journal of Hepatology</i> , 2020, 73, 490-492.	3.7	5
36	Economic and epidemiological evaluation of interventions to reduce the burden of hepatitis C in Yunnan province, China. <i>PLoS ONE</i> , 2021, 16, e0245288.	2.5	5

#	ARTICLE	IF	CITATIONS
37	Prevention of Liver Fibrosis and Cancer in Africa: The PROLIFICA project – a collaborative study of hepatitis B-related liver disease in West Africa. South African Medical Journal, 2015, 105, 185.	0.6	3
38	Letter: liver disease and COVID-19-not the perfect storm. Alimentary Pharmacology and Therapeutics, 2020, 52, 572-574.	3.7	3
39	HBV continuum of care using community- and hospital-based screening interventions in Senegal: Results from the PROLIFICA programme. JHEP Reports, 2022, 4, 100533.	4.9	3
40	Recent advances in tropical medicine. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2009, 103, 647-652.	1.8	2
41	PROLIFICA: a story of West African clinical and research collaborations to target hepatitis B-related hepatocellular carcinoma in West Africa. QJM - Monthly Journal of the Association of Physicians, 2016, 109, 373-375.	0.5	2
42	Community-based screening and treatment for chronic hepatitis B in sub-Saharan Africa – Authors' reply. The Lancet Global Health, 2017, 5, e35.	6.3	1
43	Validity of the UK early access to medicines scheme criteria for Remdesivir use in patients with COVID-19 disease. Journal of Infection, 2020, 81, 647-679.	3.3	1
44	Factors associated with reattendance to emergency services following COVID-19 hospitalization. Journal of Medical Virology, 2021, 93, 1250-1252.	5.0	1
45	Liver disease: at the heart of public health challenges for Europe in the 21st century. Lancet, The, 2022, 399, 9-10.	13.7	1
46	Commentary: how long does one need to fast before a Fibroscan examination? Authors' reply. Alimentary Pharmacology and Therapeutics, 2014, 39, 541-542.	3.7	0